Bio-Rad Laboratories (NYSE:BIO.B) Releases Earnings Results

Bio-Rad Laboratories (NYSE:BIO.B) announced its earnings results on Thursday. The company reported $2.51 EPS for the quarter, Zacks reports. The business had revenue of $693.20 million for the quarter. Bio-Rad Laboratories had a return on equity of 3.95% and a net margin of 29.42%.

Bio-Rad Laboratories Stock Performance

Bio-Rad Laboratories stock opened at $257.05 on Friday. The stock has a 50-day simple moving average of $307.35 and a 200 day simple moving average of $289.49. The stock has a market capitalization of $6.94 billion, a price-to-earnings ratio of 9.21 and a beta of 1.01. The company has a quick ratio of 3.94, a current ratio of 5.44 and a debt-to-equity ratio of 0.18. Bio-Rad Laboratories has a 12-month low of $225.29 and a 12-month high of $321.12.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc is a global provider of innovative products and systems that serve the life science research and clinical diagnostics markets. The company operates through two primary segments: Life Science, which delivers instruments, consumables and software for research applications, and Clinical Diagnostics, which offers quality control materials and reagent systems for blood typing, immunology and molecular testing. Bio-Rad’s product portfolio supports a wide range of applications, including protein analysis, gene expression, cell biology and digital PCR.

In the Life Science segment, Bio-Rad develops and markets technologies such as electrophoresis and imaging systems, chromatography instruments, laboratory consumables and software platforms that streamline experimental workflows.